- Home
- AEG vs MRNA Comparison
AEG vs MRNA Comparison
Compare AEG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEG
- MRNA
- Stock Information
- Founded
- AEG 1983
- MRNA 2010
- Country
- AEG Netherlands
- MRNA United States
- Employees
- AEG N/A
- MRNA N/A
- Industry
- AEG Life Insurance
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEG Finance
- MRNA Health Care
- Exchange
- AEG Nasdaq
- MRNA Nasdaq
- Market Cap
- AEG 12.0B
- MRNA 9.2B
- IPO Year
- AEG N/A
- MRNA 2018
- Fundamental
- Price
- AEG $7.80
- MRNA $24.62
- Analyst Decision
- AEG
- MRNA Hold
- Analyst Count
- AEG 0
- MRNA 15
- Target Price
- AEG N/A
- MRNA $36.69
- AVG Volume (30 Days)
- AEG 4.8M
- MRNA 12.2M
- Earning Date
- AEG 01-01-0001
- MRNA 11-06-2025
- Dividend Yield
- AEG 4.81%
- MRNA N/A
- EPS Growth
- AEG N/A
- MRNA N/A
- EPS
- AEG 0.93
- MRNA N/A
- Revenue
- AEG $15,344,685,849.00
- MRNA $2,232,000,000.00
- Revenue This Year
- AEG N/A
- MRNA N/A
- Revenue Next Year
- AEG $2.04
- MRNA $10.38
- P/E Ratio
- AEG $8.43
- MRNA N/A
- Revenue Growth
- AEG 2.83
- MRNA N/A
- 52 Week Low
- AEG $5.42
- MRNA $23.04
- 52 Week High
- AEG $8.15
- MRNA $48.92
- Technical
- Relative Strength Index (RSI)
- AEG 58.87
- MRNA 45.38
- Support Level
- AEG $7.50
- MRNA $23.04
- Resistance Level
- AEG $8.00
- MRNA $27.10
- Average True Range (ATR)
- AEG 0.09
- MRNA 1.61
- MACD
- AEG 0.05
- MRNA -0.02
- Stochastic Oscillator
- AEG 64.83
- MRNA 26.54
About AEG Aegon Ltd. New York Registry Shares
Aegon is a life insurance and long-term savings business listed in the Netherlands. It listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. Over recent years, Aegon has been moving through an extensive transformation program where management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the group that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile-earnings products and recycle funds into capital-light and more predictable strategic businesses.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.